CN104543674A - Health food for improving bone and joint health as well as preparation method thereof - Google Patents
Health food for improving bone and joint health as well as preparation method thereof Download PDFInfo
- Publication number
- CN104543674A CN104543674A CN201510002075.8A CN201510002075A CN104543674A CN 104543674 A CN104543674 A CN 104543674A CN 201510002075 A CN201510002075 A CN 201510002075A CN 104543674 A CN104543674 A CN 104543674A
- Authority
- CN
- China
- Prior art keywords
- health
- parts
- bone
- health food
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 42
- 235000013402 health food Nutrition 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000037180 bone health Effects 0.000 title abstract 4
- 230000037231 joint health Effects 0.000 title abstract 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 32
- 230000036541 health Effects 0.000 claims abstract description 26
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 16
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 16
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 16
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 12
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims abstract description 12
- 239000000413 hydrolysate Substances 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims description 24
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 229960003943 hypromellose Drugs 0.000 claims description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 14
- 229920003081 Povidone K 30 Polymers 0.000 claims description 14
- 229920001436 collagen Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000007888 film coating Substances 0.000 claims description 12
- 238000009501 film coating Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 45
- 239000011575 calcium Substances 0.000 description 45
- 229910052791 calcium Inorganic materials 0.000 description 45
- 201000008482 osteoarthritis Diseases 0.000 description 15
- 230000037182 bone density Effects 0.000 description 13
- 208000001132 Osteoporosis Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 102000003982 Parathyroid hormone Human genes 0.000 description 8
- 108090000445 Parathyroid hormone Proteins 0.000 description 8
- 239000000199 parathyroid hormone Substances 0.000 description 8
- 229960001319 parathyroid hormone Drugs 0.000 description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 229960002442 glucosamine Drugs 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000055008 Matrilin Proteins Human genes 0.000 description 4
- 108010072582 Matrilin Proteins Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000001582 osteoblastic effect Effects 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010031264 Osteonecrosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000537 nasal bone Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a health food for improving bone and joint health as well as a preparation method for the health food. The health food for improving the bone and joint health comprises the following components in parts by weight: 10-15 parts of glucosamine hydrochloride, 4-12 parts of chondroitin sulfate, 10-12.6 parts of calcium carbonate, 4-8 parts of collagen protein and 1-5 parts of membrana follicularis ovi hydrolysate. Proved by experience, the health food has the health function of improving the bone and joint health.
Description
Technical field
The present invention relates to health product, particularly relate to and a kind ofly improve health food of B&J health and preparation method thereof.
Background technology
Along with developing rapidly of national economy, medical and health cause constantly perfect, living standards of the people are improving constantly, and the average life span constantly extends, and aged tendency of population also becomes clear day by day.This colony of middle-aged and elderly people is going from strength to strength, and according to their physiological characteristics, body and function engender old and feeble phenomenon, and various disease also comes quiet, and osteoporosis, osteoarthritis are all the diseases threatening middle-aged and elderly people health.
Osteoporosis (osteoporosis, OP) is a kind of with bone amount minimizing, and osseous tissue fine structure destroys the one systematicness systemic skeletal disease causing skeletal fragility increase and fracture risk to increase to feature.
Osteoarthritis (osteoarthritis, OA) is the non-specific arthritis of one being narrowed feature with articular cartilage damage, subchondral osteonecrosis and joint space, is a kind of prompting aging and gradual chronic disease.
Osteoporosis can accelerate osteoarticular pathological changes, and osteoarthritis also can accelerate osteoporotic process, and the two presents complementary positive correlation.Osteoporosis and osteoarthritis are all increase relevant a kind of degeneration illness with the age, very common and can cause serious consequence in old people.Along with the aging of population, its sickness rate is more and more higher, is also the main cause causing its arthralgia and DB.
Therefore, research and development has the health food simultaneously improving B&J healthy functions, and to preventing and improving middle-aged and elderly people osteoporosis, osteoarthritis, the quality of the life improving middle-aged and elderly people is significant.
Summary of the invention
The present invention is directed to the deficiency in the middle of prior art, a kind of health food that can improve B&J health is provided.
The health food improving B&J health of the present invention, comprises each component of following weight portion:
Glucosamine hydrochloride 10 ~ 15 parts,
Chondroitin sulfate 4 ~ 12 parts,
Calcium carbonate 10 ~ 12.6 parts,
Bone collagen 4 ~ 8 parts,
Membrana Follicularis ovi hydrolysate 1 ~ 5 part.
Preferably, the health food of described improvement B&J health, also comprises the adjuvant of following weight portion:
Microcrystalline Cellulose 1.625 ~ 1.9 parts,
Carboxymethylstach sodium 0.9 ~ 2.25 part,
PVP K30 0.1 ~ 0.15 part,
Hypromellose 0.15 ~ 0.18 part,
Magnesium stearate 0.225 ~ 0.45 part,
Film coating agent 0.135 ~ 1.35 part.
Present invention also offers a kind of preparation method of the health food for described improvement B&J health, comprise the following steps:
S10, to sieve
Each raw material is crossed 60 mesh sieves respectively;
S20, granulation, drying, granulate
PVP K30 purified water is dissolved, is mixed with PVP K30 solution, for subsequent use; Hypromellose purified water is dissolved, is mixed with hypromellose cellulose solution, for subsequent use;
Calcium carbonate is mixed with hypromellose cellulose solution, soft material processed, granulate after 20 mesh sieves, obtained wet granular A; Glucosamine hydrochloride is mixed with PVP K30 solution, soft material processed, granulate after 20 mesh sieves, obtained wet granular B;
By wet granular A, wet granular B 60 ~ 70 DEG C of dryings, cross 20 mesh sieve granulate respectively, obtain granule C, granule D;
S30, always to mix
By granule C, granule D, all the other each supplementary material mix homogeneously, obtain total mixture;
S40, tabletting
Total mixture is carried out tabletting and obtains label;
S50, coating
By film coating agent purified water or dissolve with ethanol solution, stir, obtained coating solution; Again with coating solution to label film coating, obtain coated tablet.
Described Membrana Follicularis ovi hydrolysate is purchased from Jiangsu Fu Dan biological medicine company limited, and commodity are called ESM-P polypeptide powder.
The health food instructions of taking that can improve B&J health of the present invention is, oral, every day 2 times, each 2 or 3 (every sheet 0.75 gram).
Osteoporosis (osteoporosis, OP) is a kind of with bone amount minimizing, and osseous tissue fine structure destroys the one systematicness systemic skeletal disease causing skeletal fragility increase and fracture risk to increase to feature.Osteoarthritis (osteoarthritis, OA) is the non-specific arthritis of one being narrowed feature with articular cartilage damage, subchondral osteonecrosis and joint space, is a kind of prompting aging and gradual chronic disease.Osteoporosis can accelerate osteoarticular pathological changes, and osteoarthritis also can accelerate osteoporotic process, and the two presents complementary positive correlation.
Each component below in conjunction with health food of the present invention is described the mechanism that it improves B&J health.
Calcium carbonate
Calcium is the element that in human body mineral, content is maximum, is the necessary element of New bone formation in whole vital stage process of reconstruction.To the formation of sclerotin, maintain NE that is neural and muscle, reduce blood capillary and membrane passage etc. and there is important function.The calcium of 99% is present in skeleton and tooth in vivo, and the calcium of 1% is present in soft tissue and extracellular fluid, and serum calcium levels is 9-11mg/100ml, and under the adjustment of parathyroid hormone, calcitonin and vitamin D etc., its content keeps relative stability.If long-term low calcium diet, absorb less than enough calcium from food, the calcium concentration in blood will decline, in body parathyroid hormone will make skeleton and tooth separate out calcium for, to maintain calcium concentration certain in blood.Calcium in skeleton and tooth will run off gradually, makes osteopenia, causes osteoporosis and odontoseisis.
Supplementary calcium preparation is an osteoporotic Primary Care.Its mechanism mainly reduces bone conversion, suppresses the excessive secretion of parathyroid hormone, has protective effect to bone density, and can promote the formation of bone and keep bone strength.
Because calcium can suppress the secretion of parathyroid hormone, so there is anti-bone resorption.In circulation, parathyroid hormone level is seasonal variety, and appropriateness rises in the winter time, and is proportionate with the serum osteocalcin same period (mark that sclerotin upgrades).But when circulate in parathyroid hormone increase to over normal range time, then there is the bone loss of cortical bone.And the change of calcium intake within normal range time, the appropriateness of blood parathyroid hormone level can be caused to change, therefore with supplementing calcium preparation to suppress parathyroid hormone level, thus the effect of the bone mass of stabilization of bony cortex can be played.
Glucosamine hydrochloride
Glucosamine is a kind of natural amino monosaccharide, it is the composition of poly-glucosamine in cartilage matrix and synovial fluid, chondrocyte synthetic proteins polysaccharide can be stimulated, supplement the loss of cartilage matrix, suppress the enzyme of damaged cartilage as collagenase and phospholipase A2, and the generation of the super oxyradical of damaged cartilage cell can be prevented, thus promote the repair and reconstruction of cartilage matrix, improve joint motion, alleviating pain.
Osteoblast is as the key player participating in bone metabolism, and its differentiation and maturation, functional activity and apoptosis determine formation and the mineralization degree of bone in metabolic process.Research in recent years shows, glucosamine has the effect improving osteoblast activity, promote osteoblastic proliferation.
Glucosamine is general in vitro to be existed with the form of sulphuric acid, hydrochloric acid, N-acetylate, and they dissociate completely in gastric acid, absorb in small intestinal with glucosamine original shape, just have nothing to do with initial acid group, show identical activity once by absorption.
Chondroitin sulfate
Chondroitin sulfate is the class mucopolysaccharide be extensively present in humans and animals cartilaginous tissue, the class acidic mucopolysaccharide obtained primarily of cartilaginous tissue separation and purification such as animal larynx bone, nasal septum, tracheas, the structure of chondroitin sulfate is made up of D-glucuronic acid and N-2 acyl-D chondrosaminicacid sulfuric ester.Its composition is about containing 50-70 disaccharidase ultimate unit, and molecular weight is 1-5 ten thousand.According to the difference of alduronic acid kind and sulfuric ester position in its molecular structure, be mainly divided into three types: chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C etc.There is composition as natural in connective tissue in chondroitin sulfate, can be used for lubrication and support joint by bound water molecule, make joint motion freely; and there is promotion osteoblastic proliferation, promote bone doped calcium, induction new bone formation; protection cartilage, antiinflammatory, the multiple biological activity such as blood fat reducing.In recent years, chondroitin sulfate, as a kind of novel active composition, is subject to people's attention gradually and welcomes.
Bone collagen
Bone collagen is also called as tectine matter, is skeleton, articular cartilage, epiphysial cartilage and bone trabecular main constituent, has 70% ~ 86% to be bone collagen in skeleton Organic substance.Bone collagen in osteocyte is the adhesive of hydroxyapatite, and itself and hydroxyapatite together constitute the main body of skeleton.Bone collagen is mainly distributed in spongy bone in skeleton, and collagen content increases, and bone trabecula can be made thickening, and toughness increases.Collagen is full of the net of duck eye just as in skeleton, and it can keep the mineral such as calcium, phosphorus that will run off firmly here.The characteristic amino acid hydroxyproline of collagen protein is the vehicle of transport calcium to osteocyte.Research shows, if collagen protein is less in bone, even if supplement calcareous how also little for preventing osteoporosis effect again.Therefore, while replenishing the calcium, take in a certain amount of collagen protein, be conducive to absorption and the deposition of calcium.
Membrana Follicularis ovi hydrolysate
Membrana Follicularis ovi derives from the eggshell inner membrance of Phasianidae animal man chicken.Membrana Follicularis ovi is about containing protein 90%, liposome 3%, saccharide 2%, aminoacid kind more than 20, and egg shell membrane is based on collagen protein, keratin, the compound protein that combines with mucopolysaccharide class.Contain and constituent identical or close in knee cartilage substrate and joint fluid, as glucosamine, hyaluronic acid, chondroitin sulfate, collagen protein etc.Clinical trial confirms, oral Membrana Follicularis ovi can improve the gonalgia of Human Osteoarthritis and stiff symptom, and safe and effective.Membrana Follicularis ovi hydrolysate may secrete inflammatory mediator with its suppression OA to the protective effect of articular cartilage, and reduces the destruction of inflammatory mediator to cartilage matrix, promotes that chondrocyte synthesis secretion proteoglycan is relevant.
The primary raw material of this product is calcium carbonate, glucosamine hydrochloride and chondroitin sulfate, bone collagen and Membrana Follicularis ovi hydrolysate.Calcium carbonate is conventional calcium source, can effectively prevent bone calcium loss by replenishing the calcium, and increases bone doped calcium, increases bone amount, to prevent and delaying osteoporosis plays an important role; Glucosamine hydrochloride and chondroitin sulfate can promote osteoblastic proliferation, improve osteoblast activity, finally reach the function improving B&J health, bone collagen is conducive to absorption and the deposition of calcium, Membrana Follicularis ovi hydrolysate contains and constituent identical or close in knee cartilage substrate and joint fluid, as glucosamine, hyaluronic acid, chondroitin sulfate, collagen protein etc., the gonalgia of Human Osteoarthritis and stiff symptom can be improved, above five kinds of raw materials share, and can effectively improve B&J health.
Detailed description of the invention
Below in conjunction with embodiment, technical scheme of the present invention is further elaborated.
Embodiment 1
The Ricipe for health care food that can improve B&J health of the present embodiment is:
Glucosamine hydrochloride 13.5 parts,
Chondroitin sulfate 9 parts,
Calcium carbonate 12.6 parts,
Bone collagen 4 parts,
Membrana Follicularis ovi hydrolysate 1 part.
Microcrystalline Cellulose 1.885 parts,
Carboxymethylstach sodium 2.25 parts,
PVP K30 0.135 part,
Hypromellose 0.18 part,
Magnesium stearate 0.45 part,
Film coating agent 1.35 parts.
The health food that can improve B&J health of the present embodiment is prepared according to following steps:
S10, to sieve
Each raw material is crossed 60 mesh sieves respectively;
S20, granulation, drying, granulate
PVP K30 purified water is dissolved, is mixed with PVP K30 solution, for subsequent use; Hypromellose purified water is dissolved, is mixed with hypromellose cellulose solution, for subsequent use;
Calcium carbonate is mixed with hypromellose cellulose solution, soft material processed, granulate after 20 mesh sieves, obtained wet granular A; Glucosamine hydrochloride is mixed with PVP K30 solution, soft material processed, granulate after 20 mesh sieves, obtained wet granular B;
By wet granular A, wet granular B 60 ~ 70 DEG C of dryings, cross 20 mesh sieve granulate respectively, obtain granule C, granule D;
S30, always to mix
By granule C, granule D, all the other each supplementary material mix homogeneously, obtain total mixture;
S40, tabletting
Total mixture is carried out tabletting and obtains label;
S50, coating
By film coating agent 70wt% (wt mass percent) dissolve with ethanol, stir, obtained coating solution; Again with coating solution to label film coating, obtain coated tablet.
Embodiment 2
The Ricipe for health care food that can improve B&J health of the present embodiment is:
Glucosamine hydrochloride 10 parts,
Chondroitin sulfate 12 parts,
Calcium carbonate 10 parts,
Bone collagen 8 parts,
Membrana Follicularis ovi hydrolysate 2 parts.
Microcrystalline Cellulose 1.625 parts,
Carboxymethylstach sodium 0.9 part,
PVP K30 0.1 part,
Hypromellose 0.15 part,
Magnesium stearate 0.225 part,
Film coating agent 0.135 part.
The preparation method can improving the health food of B&J health of the present embodiment is with embodiment 1.
Embodiment 3
The Ricipe for health care food that can improve B&J health of the present embodiment is:
Glucosamine hydrochloride 15 parts,
Chondroitin sulfate 4 parts,
Calcium carbonate 11 parts,
Bone collagen 6 parts,
Membrana Follicularis ovi hydrolysate 5 parts.
Microcrystalline Cellulose 1.9 parts,
Carboxymethylstach sodium 1.35 parts,
PVP K30 0.15 part,
Hypromellose 0.15 part,
Magnesium stearate 0.45 part,
Film coating agent 0.135 part.
The preparation method can improving the health food of B&J health of the present embodiment is with embodiment 1.
The film coating agent used in embodiment 1 ~ 3 is hypromellose or coating pre-mixing agent.
Increase bone density test
1 materials and methods
1.1 samples: the health food in embodiment 1, human body recommended dose be 4.5g/ day/people.
1.2 experimental animals and raising: SPF level female sd inbred rats 60.Animal feeding: animal is raised in barrier level (IVC) Animal House.In whole experimentation, animal freely ingests and drinks deionized water, room temperature 20 DEG C ~ 26 DEG C, relative humidity 40% ~ 70%.
1.3 feedstuffs: low calcium feedstuff, is provided by institute of lab animals of Sichuan Academy of Medical Sciences.Low calcium feed formula (gram %): casein 10.0, analysis for soybean powder 15.0, wheat flour 54.0, Oleum Arachidis hypogaeae semen 4.0, cellulose 2.0, AIN
_ 76salt-mixture 2.6, AIN
-76mixed vitamin 1.0, choline chloride 0.2, DL-methionine 0.2, starch 11.0, actual measurement per kilogram feedstuff calcium content is 789.5mg, adds CaC0
3feed calcium content is made to reach actual measurement 1500mg/kg, as low calcium feedstuff.
1.4 key instruments and reagent: atomic absorption spectrophotometer, DPX-L Dual-energy X-rays absorptionmetry, electronics Libra.
1.5 experimental techniques: rat after seven days, according to body weight, is divided into following five groups with normal feedstuff adaptability feed at random:
Low calcium matched group, high dose calcium carbonate group, health food three dosage groups that can increase bone density of the present invention: 375mg/kg.bw group, 750mg/kg.bw group and 1500mg/kg.bw group (being equivalent to 5,10,20 times of human intaking amount 75mg/kg.bw respectively), every treated animal 12.Five treated animals are all with low calcium feedstuff feed.Low calcium matched group is with distilled water gavage; Three dosage groups are with (the preparation of gavage liquid: get respectively and close brightness board nutritious calcium tablet (fragrant citrus taste) 3.75g, 7.5g, 15.0g of the sample liquid gavage of preparation, adding distil water is settled to 100ml, is mixed with the gavage liquid of 375mg/kg.bw, 750mg/kg.bw, 1500mg/kg.bw group); High dose calcium carbonate control group per os pours into the calcium carbonate of 375mg/kg.bw, and this dosage is equivalent to this health food high dose group calcium level.All animal gavage amounts are 10ml/kg.bw; Once a day, continuous gavage 90 days, weighs weekly and adjusts gavage amount by body weight.Test last femoral artery sacrificed by exsanguination animal, take out right side femur, in 105 DEG C of baking ovens, bake to constant weight, weigh bone weight.Bian DPX-L Dual-energy X-rays absorptionmetry measures fl bone density (g/cm
2), its concrete assay method scans whole fl with DPX-L Dual-energy X-rays absorptionmetry, represents this bone bone density with the mean bone density of bone.The right femur calcium content of Bian atomic absorption spectroscopy determination.
1.6 experimental data statistics: use PEMS3.1 statistical package, variance analysis is done to the group difference of each index.
2 results
The impact that 2.1 health foods of the present invention weigh rat body weight, bone, in table 1.
The impact that table 1 weighs rat body weight, bone
From table 1, body weight there was no significant difference (P>0.05) before each group experiment; After experiment, each group body weight also there was no significant difference (P>0.05).Three dosage groups have rising trend with the right femur bone of high dose calcium carbonate group is heavy compared with low calcium matched group, but not statistically significant (P>0.05).
2.2 health foods of the present invention on the impact of rat bone density and bone calcium, in table 2.
Table 2 is on the impact of rat bone density and calcium content of bone
★: compare P<0.05 with low calcium matched group; ★ ★: compare P<0.01 with low calcium matched group
From table 2, the bone density of high dose calcium carbonate group is significantly higher than low calcium matched group (P<0.05), the bone density of health food of the present invention middle and high dosage group is significantly higher than low calcium matched group (P<0.01, P<O.05), and without significant difference (P>0.05) between high dose group fl bone density and high dose calcium carbonate control group.There was no significant difference (P>0.05) between the right femur calcium content of three dosage groups and high dose calcium carbonate group and low calcium matched group.
3 brief summaries
The fl bone density of health food of the present invention middle and high dosage group is significantly higher than low calcium matched group (P<0.01, P<0.05), high dose group fl bone density compares without significant difference (P>0.05) with high dose calcium carbonate control group.By evaluation criterion: health food of the present invention has increase bone substance density improving function.
Improve osteoarthrosis test
1 clinical data
Object of study is Beijing person in middle and old age Osteoarthritis.Number 20 example.Screening conditions: do not take any D-glucosamine chrondroitin series products confirms to have osteoarthritis middle-older patient through Clinical Laboratory.Data statistics tests and assesses 8: during rest, pain, fortune oxycinesia, articular pain, arthroncus, joint deadlock in morning, locomotor activity, crouching play obstacle, stair activity, have one or more symptom improver to be effectively with user is every.
The instructions of taking of 2 patients and statistical effect
2.1 instructions of taking: take the health food 2 times/d in embodiments of the invention 1,3 pieces/times.
2.2 take effect follows the tracks of statistical data in Table 3-table 5.
Table 3 patient takes health food 28d symptom of the present invention and improves data statistics
Table 4 patient takes health food 28d total effective rate of the present invention statistics
Table 5 patient takes the health food of the present invention osteoarthritis symptoms of 2 months and improves statistics
3 brief summaries
Health food of the present invention has the function improving osteoarthritic inflammation.
The sequencing of above embodiment, only for ease of describing, does not represent the quality of embodiment.
Last it is noted that above embodiment is only in order to illustrate technical scheme of the present invention, be not intended to limit; Although with reference to previous embodiment to invention has been detailed description, those of ordinary skill in the art is to be understood that: it still can be modified to the technical scheme described in foregoing embodiments, or carries out equivalent replacement to wherein portion of techniques feature; And these amendments or replacement, do not make the essence of appropriate technical solution depart from the spirit and scope of various embodiments of the present invention technical scheme.
Claims (3)
1. improve a health food for B&J health, it is characterized in that, comprise each component of following weight portion:
Glucosamine hydrochloride 10 ~ 15 parts,
Chondroitin sulfate 4 ~ 12 parts,
Calcium carbonate 10 ~ 12.6 parts,
Bone collagen 4 ~ 8 parts,
Membrana Follicularis ovi hydrolysate 1 ~ 5 part.
2. the health food improving B&J health according to claim 1, is characterized in that, also comprises the adjuvant of following weight portion:
Microcrystalline Cellulose 1.625 ~ 1.9 parts,
Carboxymethylstach sodium 0.9 ~ 2.25 part,
PVP K30 0.1 ~ 0.15 part,
Hypromellose 0.15 ~ 0.18 part,
Magnesium stearate 0.225 ~ 0.45 part,
Film coating agent 0.135 ~ 1.35 part.
3. a preparation method for the health food of the improvement B&J health described in claim 1 or 2, is characterized in that, comprise the following steps:
S10, to sieve
Each raw material is crossed 60 mesh sieves respectively;
S20, granulation, drying, granulate
PVP K30 purified water is dissolved, is mixed with PVP K30 solution, for subsequent use; Hypromellose purified water is dissolved, is mixed with hypromellose cellulose solution, for subsequent use;
Calcium carbonate is mixed with hypromellose cellulose solution, soft material processed, granulate after 20 mesh sieves, obtained wet granular A; Glucosamine hydrochloride is mixed with PVP K30 solution, soft material processed, granulate after 20 mesh sieves, obtained wet granular B;
By wet granular A, wet granular B 60 ~ 70 DEG C of dryings, cross 20 mesh sieve granulate respectively, obtain granule C, granule D;
S30, always to mix
By granule C, granule D, all the other each supplementary material mix homogeneously, obtain total mixture;
S40, tabletting
Total mixture is carried out tabletting and obtains label;
S50, coating
By film coating agent purified water or dissolve with ethanol solution, stir, obtained coating solution; Again with coating solution to label film coating, obtain coated tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510002075.8A CN104543674A (en) | 2015-01-04 | 2015-01-04 | Health food for improving bone and joint health as well as preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510002075.8A CN104543674A (en) | 2015-01-04 | 2015-01-04 | Health food for improving bone and joint health as well as preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104543674A true CN104543674A (en) | 2015-04-29 |
Family
ID=53061598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510002075.8A Pending CN104543674A (en) | 2015-01-04 | 2015-01-04 | Health food for improving bone and joint health as well as preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104543674A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770850A (en) * | 2016-04-25 | 2016-07-20 | 南京邦康生物技术有限公司 | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product |
| CN106213492A (en) * | 2016-07-22 | 2016-12-14 | 山东博奥克生物科技有限公司 | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density |
| CN106333962A (en) * | 2016-10-29 | 2017-01-18 | 芜湖市诺康生物科技有限公司 | Composition for increasing bone density |
| CN109007821A (en) * | 2018-08-07 | 2018-12-18 | 青岛明月海藻生物科技有限公司 | A kind of gel jelly and preparation method thereof improving articulation health |
| CN109480213A (en) * | 2018-12-13 | 2019-03-19 | 北京康比特体育科技股份有限公司 | A kind of sport nutrition matched combined object with joint maintenance and maintenance |
| CN110946994A (en) * | 2019-12-30 | 2020-04-03 | 东营广元生物科技股份有限公司 | Composition for increasing bone mineral density and preparation method thereof |
| CN114191543A (en) * | 2021-12-14 | 2022-03-18 | 云南欣乐佳生物科技有限公司 | Composition with articular cartilage repairing function and preparation and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949710A (en) * | 2012-05-08 | 2013-03-06 | 北京润康普瑞生物技术有限公司 | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product |
| CN104068306A (en) * | 2014-06-18 | 2014-10-01 | 广州市赛健生物科技有限公司 | Health food for improving bone density and preparation method of health food |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN104206949A (en) * | 2014-08-04 | 2014-12-17 | 江苏康缘阳光药业有限公司 | Composition for improving osteoporosis and increasing bone mineral density, preparation method of same and application of the same in preparation of health-caring product |
-
2015
- 2015-01-04 CN CN201510002075.8A patent/CN104543674A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949710A (en) * | 2012-05-08 | 2013-03-06 | 北京润康普瑞生物技术有限公司 | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product |
| CN104068306A (en) * | 2014-06-18 | 2014-10-01 | 广州市赛健生物科技有限公司 | Health food for improving bone density and preparation method of health food |
| CN104206949A (en) * | 2014-08-04 | 2014-12-17 | 江苏康缘阳光药业有限公司 | Composition for improving osteoporosis and increasing bone mineral density, preparation method of same and application of the same in preparation of health-caring product |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李奕修等: "灌胃凤凰衣水解物对膝骨关节炎模型大鼠影响的实验研究", 《中国中医骨伤科杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770850A (en) * | 2016-04-25 | 2016-07-20 | 南京邦康生物技术有限公司 | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product |
| CN106213492A (en) * | 2016-07-22 | 2016-12-14 | 山东博奥克生物科技有限公司 | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density |
| CN106333962A (en) * | 2016-10-29 | 2017-01-18 | 芜湖市诺康生物科技有限公司 | Composition for increasing bone density |
| CN109007821A (en) * | 2018-08-07 | 2018-12-18 | 青岛明月海藻生物科技有限公司 | A kind of gel jelly and preparation method thereof improving articulation health |
| CN109480213A (en) * | 2018-12-13 | 2019-03-19 | 北京康比特体育科技股份有限公司 | A kind of sport nutrition matched combined object with joint maintenance and maintenance |
| CN110946994A (en) * | 2019-12-30 | 2020-04-03 | 东营广元生物科技股份有限公司 | Composition for increasing bone mineral density and preparation method thereof |
| CN114191543A (en) * | 2021-12-14 | 2022-03-18 | 云南欣乐佳生物科技有限公司 | Composition with articular cartilage repairing function and preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104543674A (en) | Health food for improving bone and joint health as well as preparation method thereof | |
| CN101856128B (en) | Health food for increasing bone density and preparation method thereof | |
| CN102552877A (en) | Health-care preparation for improving osteoporosis and increasing bone density and preparation method thereof | |
| CN103039976A (en) | Healthcare food for increasing bone density and preparation method thereof | |
| Tomaszewska et al. | The influence of the dietary cu-glycine complex on the histomorphology of cancellous bone, articular cartilage, and growth plate as well as bone mechanical and geometric parameters is dose dependent | |
| Hernigou et al. | Vitamin D history part III: the “modern times”—new questions for orthopaedic practice: deficiency, cell therapy, osteomalacia, fractures, supplementation, infections | |
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| CN102805858B (en) | High-efficiency calcium supplement capsule and preparation method thereof | |
| CN105079028A (en) | Health care product capable of improving bones and joints and preparation method of health care product | |
| CN102894372A (en) | Health-care food for increasing bone density and preparation method thereof | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| CN107348522A (en) | A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof | |
| CN102551045B (en) | Collagen calcium tablet | |
| WO2013136871A1 (en) | Oversulfated chondroitin composition | |
| KR20050044589A (en) | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis | |
| KR101513855B1 (en) | A composition for the treatment or prevention of osteoarthrits comprising an extract of crinum asiaticum | |
| CN1669478A (en) | Preparation method of vinegar-egg powder, compound containing vinegar-egg powder and application thereof | |
| CN104824677A (en) | Bone density increase health food and preparation method thereof | |
| US7011853B2 (en) | Putamen ovi | |
| CN101401833A (en) | Composition for preventing and/or treating osteoporosis | |
| CN101692907A (en) | High-activity yak marrow bio-calcium compound capsule | |
| CN105770850A (en) | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product | |
| Anderson et al. | Nutritional osteodystrophy in captive green iguanas (Iguana iguan a) | |
| RU2404788C2 (en) | Composition with general health-improving effect | |
| JP2005232089A (en) | Orally administrable functional agent having bone quantity-increasing activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150429 |
|
| RJ01 | Rejection of invention patent application after publication |